Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

William Rosenberger

Ophthalmology Prince George, VA Medical Doctor

NPI 1730286048 CMS profile 124404

2015 Waterside Rd, Prince George, VA 23875

Open in the dashboard

General payments

$11,026

26 records reported · program years 2019–2024

Research payments

$7,425

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, William Rosenberger of Prince George, VA is reported in the CMS Open Payments database as having received $11,026 across 26 general payments and $7,425 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $195 2
2023 General $112 5
2022 General $178 1
2022 Research $3,375 1
2021 General $2,869 4
2020 General $7,504 7
2020 Research $4,050 1
2019 General $168 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Rosenberger
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to William Rosenberger were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year William Rosenberger Ophthalmology median Middle half National median
2019 $168 $258 $104–$655 $163
2020 $7,504 $126 $45–$321 $114
2021 $2,869 $205 $76–$534 $132
2022 $178 $266 $100–$678 $149
2023 $112 $308 $117–$745 $160
2024 $195 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amgen Inc. $5,288 2 payments
  2. Haemonetics Corporation $5,000 4 payments
  3. Alcon Vision LLC $348 7 payments
  4. New World Medical,Inc. $178 1 payment
  5. Horizon Therapeutics plc $55 3 payments
  6. Aerie Pharmaceuticals, Inc. $44 3 payments
  7. Allergan Inc. $29 2 payments
  8. Mallinckrodt Hospital Products Inc. $29 1 payment
  9. Sight Sciences, Inc. $20 1 payment
  10. Novartis Pharmaceuticals Corporation $19 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $10,288 6 payments
  2. Food and Beverage $714 19 payments
  3. Education $24 1 payment
Products named General payments · program years 2019–2024
  1. Plasma $5,000 4 payments
  2. Clareon $189 2 payments
  3. Kahook Dual Blade $178 1 payment
  4. Ahmed Glaucoma Valve $178 1 payment
  5. Streamline Surgical System $178 1 payment
  6. PANOPTIX $76 1 payment
  7. TEPEZZA $55 3 payments
  8. HYDRUS Microstent $46 2 payments
  9. LUMIGAN $29 2 payments
  10. ACTHAR $29 1 payment
  11. Other $167 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Amgen Inc. $7,425 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,534

Median for Ophthalmology: 891

Drug cost

$78,887

Median for Ophthalmology: $68,233

Branded share of claims

17.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 16 $20,450
Cyclosporine Generic 11 $13,480
Lumigan Bimatoprost Brand 25 $12,027
Latanoprost Generic 946 $10,230
Brimonidine Tartrate Generic 69 $5,860
Rhopressa Netarsudil Mesylate Brand 11 $5,094
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 195 $3,045
Alphagan P Brimonidine Tartrate Brand 12 $2,958
Timolol Maleate Generic 169 $2,097
Travoprost Generic 12 $1,811

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record